Search Results
Your search for A matches 32922 pages
Showing 9851 - 9900Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma
In the phase II NRG Oncology HN002 trial reported in the Journal of Clinical Oncology, Sue S. Yom, MD, PhD, and colleagues found that a reduced-dose intensity-modulated radiation therapy (IMRT) regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma satisfied...
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with the combination of fixed-duration venetoclax/rituximab had a longer overall survival and progression-free survival at 5 years compared with those treated with bendamustine/rituximab, according to a 5-year analysis...
Janet Woodcock, MD, Named Acting FDA Commissioner
Janet Woodcock, MD, current Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA), has been named acting FDA Commissioner, according to a report published in The New York Times.1Stephen M. Hahn, MD, who had been FDA Commissioner since December 17,...
MAPK/ERK Inhibitor Mirdametinib in Adolescents and Adult Patients With NF1-Related Plexiform Neurofibromas
In the Neurofibromatosis Clinical Trials Consortium phase II NF106 trial, reported in the Journal of Clinical Oncology, Weiss et al found evidence of activity of the oral MAPK/ERK kinase inhibitor mirdametinib in adolescents and adult patients with neurofibromatosis type 1 (NF1)-related plexiform...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
HERO-TOGETHER: Opportunity for Health-Care Workers to Share Their Experience With COVID-19 Vaccination
HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people fare after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health-care providers everywhere have worked together to face. On the...
Jill Feldman on Diversifying the Criteria for Inclusion in Clinical Trials
Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved communities in clinical trial research (Abstract PL04.06).
Five-Year Outcomes From the CheckMate 017 and 057 Trials of Nivolumab vs Docetaxel in Previously Treated Patients With NSCLC
In an analysis of the phase III CheckMate 017 and 057 trials in previously treated patients with advanced squamous (017) and nonsquamous (057) non–small cell lung cancer (NSCLC), reported in the Journal of Clinical Oncology, Hossein Borghaei, DO, MS, and colleagues found pooled 5-year overall...
Role of Twitter in Identifying Barriers to Care Among Patients With Metastatic Breast Cancer
Information shared by women with metastatic breast cancer on social media platforms like Twitter may be a timely source of data for policymakers hoping to improve care and outcomes for these patients, according to a study published by Shimkhada et al in JMIR Public Health and Surveillance. Role of...
Breast Cancer–Specific Mortality by Race/Ethnicity and 21-Gene Recurrence Scores
In a U.S. population–based cohort study reported in JAMA Oncology, Hoskins et al found that among patients with estrogen receptor–positive breast cancer, Black women were more likely than White women to have a high Oncotype DX 21-gene recurrence score. Researchers also found that breast...
Mental Health–Related Symptoms Among Cancer Survivors During the First Wave of the COVID-19 Pandemic in the United States
In an analysis from the COVID-19 Impact Survey reported in JCO Oncology Practice, Islam et al found that U.S. adult cancer survivors were more likely to report mental health–related symptoms vs adults without cancer during the first wave of the COVID-19 pandemic. Study Details Data for the analysis ...
Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk
At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...
Lisocabtagene Maraleucel Approved by FDA for Patients With Relapsed or Refractory Large B-Cell Lymphoma
On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not...
FDA Grants Accelerated Approval to Umbralisib for Treatment of Marginal Zone and Follicular Lymphomas
On February 5, the U.S. Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq), a kinase inhibitor including PI3K-delta and CK1-epsilon, for the following indications: Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior...
IASLC WCLC 2020: Updates From the ADAURA Trial and More
This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.
Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract...
FDA Update: Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate, Statement on Product Development to Address Virus Variants
On February 4, the U.S. Food and Drug Administration (FDA) announced the scheduling of a meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization for a COVID-19 vaccine from Janssen Biotech Inc. Additionally, Acting...
Study Shows Aspirin Use Before Diagnosis May Lower Colorectal Cancer Mortality
A recent study found that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower colorectal cancer–specific mortality. The report, published by Figueiredo et al in JNCI: The Journal of the National Cancer Institute, suggests that the findings for prediagnosis...
HIC Assays May Aid in Predicting Response to Immunotherapy Among Patients With NSCLC
Using a host immune classifier (HIC) test for patients with non–small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented by Akerley et al at the International Association for the Study of Lung Cancer (IASLC) 2020 World...
Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection
B-cell–depleting immunotherapy may cause B-cell aplasia and impair the body’s immune response. A retrospective, multicentric French study of patients with lymphoma and persistent COVID-19 infection has found that those treated with B-cell–depleting therapies within the previous 12 months had nearly ...
Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection
Due to concerns that patients with cancer may be at higher risk for contracting the coronavirus—and may have more severe complications if infected—during the COVID-19 pandemic, hospitals and clinical practices have changed protocols to routine cancer care to reduce patients’ exposure to the virus....
Socially Distant Drive-by FluFIT Clinics May Increase Colorectal Cancer Screening Rates Among Black Patients During the COVID-19 Pandemic
Administering colorectal cancer screening kits through a socially distant drive-by flu vaccination clinic increased access to colorectal cancer screening among Black Americans, according to results presented by Washington et al at the AACR Virtual Meeting: COVID-19 and Cancer (Abstract S02-04)....
Study Finds More Than Half of U.S. Cancer Survivors Have Underlying Medical Conditions Associated With Severe COVID-19 Illness
A recent study has found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness. The report, published by Jiang et al in JNCI: The Journal of the National Cancer Institute, suggested that...
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
Germline Whole-Exome Sequencing Reveals the Potential Role of Hereditary Predisposition and Therapeutic Implications in SCLC
A study presented by Nobuyuki Takahashi, MD, of the Center for Cancer Research at the National Cancer Institute, at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore (Abstract OA11.05) demonstrated that there may be an inherited ...
Patient-Reported Outcomes From the CROWN Trial: First-Line Lorlatinib vs Crizotinib for ALK-Positive NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration in chest pain, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented at the International Association for the Study of...
Development and Performance of a Population-Based Benchmark Model for Use of Cancer Surgery in High-Income Countries
In a study reported in The Lancet Oncology, Perera et al developed a population-based benchmark model for guideline-recommended use of surgery for primary cancers in high-income countries. Actual use of surgery was often consistent with model predictions but sometimes varied markedly. Study ...
Changes in Radiotherapy Use in England During the First Peak of the COVID-19 Pandemic
In a population-based study reported in The Lancet Oncology, Spencer et al found that mean weekly radiotherapy courses for cancer and attendance for receipt of fractions declined significantly during the first peak of the COVID-19 pandemic in England. However, use of hypofractionated radiotherapy...
Long-Term Quality of Life With Ultrahypofractionated vs Conventionally Fractionated Radiotherapy for Prostate Cancer
As reported in The Lancet Oncology by Fransson et al, analysis of patient-reported quality of life in the Scandinavian phase III HYPO-RT-PC trial showed no significant differences at up to 6 years of follow-up between patients receiving ultrahypofractionated radiotherapy vs conventionally...
Taiwanese TALENT Study Supports Effectiveness of Low-Dose CT for Lung Cancer in Certain Populations
A study presented by researchers with the Ministry of Health and Welfare in Taiwan confirmed low-dose computed tomography (CT) screening may be feasible in a predefined, never-smoking, high-risk population. The research was presented at the International Association for the Study of Lung Cancer...
Two ADAURA Analyses Support the Use of Osimertinib in Patients With Surgically Resected NSCLC
Two presentations based on data from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival outcomes for patients with surgically resected non–small cell lung cancer (NSCLC) receiving osimertinib, while also maintaining quality of life. The data were...
FDA Grants Accelerated Approval to Tepotinib for Patients With Metastatic NSCLC and MET Exon 14–Skipping Alterations
On February 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations. VISION Trial Efficacy was...
Margetuximab-cmkb vs Trastuzumab in Heavily Pretreated Patients With HER2-Positive Breast Cancer: SOPHIA Trial
As reported in JAMA Oncology by Hope S. Rugo, MD, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who experienced disease...
Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk
In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...
New Burkitt Lymphoma International Prognostic Index
As reported by Olszewski et al in the Journal of Clinical Oncology, members of The Burkitt Lymphoma International Prognostic Index Consortium have developed an index—the Burkitt Lymphoma International Prognostic Index (BL-IPI)—that provides “robust discrimination of survival” among adult patients...
Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of ...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
WCLC Press Briefing Focuses on the Connection Between Lung Cancer and COVID-19
On February 27, 2020, the Journal of Thoracic Oncology published a case study that described two patients from Wuhan, China, who had recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. Eleven months later, the lung...
Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma
In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...
LCMC3 Trial: Neoadjuvant Atezolizumab for Patients With Stage IB to IIIB Resectable Lung Cancer
Neoadjuvant treatment with single-agent atezolizumab for patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and pathologic complete response rate of 7% in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study. The findings were...
Adolescent and Young Adult Cancer Survivors Are at Increased Risk for Adverse Mental Health Outcomes
According to the National Cancer Institute, in 2020, 89,500 adolescents and young adults (AYAs) aged 15 to 39 were diagnosed with cancer, and of these, 84.6% are expected to survive their cancer for 5 years after diagnosis. However, the results from a study by De et al published in the Journal of...
Emil J Freireich, MD, Dies at 93
Emil J Freireich, MD, an oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized as a founding father of modern clinical cancer research, passed away on February 1. He was 93. Dr. Freireich was a faculty member at The University of Texas MD Anderson Cancer ...
Addition of Wee1 Inhibitor Adavosertib to Gemcitabine in Platinum-Resistant/Refractory Recurrent Ovarian Cancer
In a phase II trial reported in The Lancet, Lheureux et al found that the addition of the oral Wee1 inhibitor adavosertib to gemcitabine significantly improved progression-free survival in patients with platinum-resistant/refractory recurrent ovarian cancer. As related by the investigators, the...
Lenalidomide Plus Subcutaneous Rituximab-MiniCHOP in Patients Aged 80 or Older With DLBCL
In the French phase III SENIOR trial reported in the Journal of Clinical Oncology, Oberic et al found that the addition of lenalidomide to subcutaneous rituximab plus attenuated-dose CHOP (mini-CHOP; cyclophosphamide, doxorubicin, vincristine, prednisone) did not improve overall survival in...
Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given decreases in mortality rates, widespread use of targeted treatments and immunotherapies, and earlier diagnoses as a result of ...
Featured Presentations at WCLC Focus on Disparities in Patients With Lung Cancer
At a press briefing held by the International Association for the Study of Lung Cancer (IASLC), researchers presented new data that revealed factors relating to race, gender, sexual orientation, and income continue to be significant barriers to those living with lung cancer. The press briefing is...
Negative Findings in KEYNOTE-598: Ipilimumab Adds No Benefit to Pembrolizumab as First-Line Therapy for NSCLC With High PD-L1 Expression
In the phase III KEYNOTE-598 study, the addition of ipilimumab to pembrolizumab increased toxicity without boosting efficacy as first-line therapy for metastatic non–small cell lung cancer (NSCLC) in patients with high expression of PD-L1, according to research presented at International...
Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC
The phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in patients with advanced non–small cell lung cancer (NSCLC). In a follow-up to phase I data, the phase II cohort of the study has now shown a durable response rate of 37.1%, a disease control rate...
Outcomes and Patterns of Relapse in Pediatric Medulloblastoma
In a study reported in the Journal of Clinical Oncology, Kumar et al identified outcomes and patterns of relapse in pediatric patients with medulloblastoma. The investigators found that time to relapse and postrelapse survival was associated with subgroup and that the majority of relapses involve...
First-in-Class Eprenetapopt Plus Azacitidine for TP53-Mutant Myelodysplastic Syndromes
In a phase Ib/II study reported in the Journal of Clinical Oncology, David A. Sallman, MD, and colleagues found that the combination of azacitidine and the first-in-class small-molecule agent eprenetapopt produced high response rates in patients with TP53-mutant myelodysplastic syndromes (MDS)....
